Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer
Journal of Cancer Research & Clinical Oncology, 03/19/2012Manzoni M et al.
The authors confirmed the predictive role of an increase in circulating endothelial cell (CEC) in metastatic colorectal cancer (mCRC) patients treated with Bevacizumab–based therapy and showed that modifications in CECs and circulating endothelial cell (CEC) number, their apoptotic fraction (APO–CEC) are independent factors. This underlines the relevance of a simultaneous quantitative and functional evaluation of these biomarkers in view of their possible diagnostic utility.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.